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Abstract
Alanine-glyoxylate aminotransferase is a peroxisomal enzyme, of which various missense mutations lead to irreversible
kidney damage via primary hyperoxaluria type 1, in part caused by improper peroxisomal targeting. To unravel the
molecular mechanism of its recognition by the peroxisomal receptor Pex5p, we have determined the crystal structure of the
respective cargo–receptor complex. It shows an extensive protein/protein interface, with contributions from residues of the
peroxisomal targeting signal 1 and additional loops of the C-terminal domain of the cargo. Sequence segments that are
crucial for receptor recognition and hydrophobic core interactions within alanine-glyoxylate aminotransferase are
overlapping, explaining why receptor recognition highly depends on a properly folded protein. We subsequently
characterized several enzyme variants in vitro and in vivo and show that even minor protein fold perturbations are sufficient
to impair Pex5p receptor recognition. We discuss how the knowledge of the molecular parameters for alanine-glyoxylate
aminotransferase required for peroxisomal translocation could become useful for improved hyperoxaluria type 1 treatment.
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Introduction
Primary hyperoxaluria type 1 (PH1) is an autosomal recessive
disorder that generally becomes symptomatic during childhood or
adolescence and ultimately leads to renal failure, usually between
the ages of 25 and 45 [1]. Although several therapeutic options
have been established, the only curative treatment to date is by
liver-kidney transplantation [2]. At the molecular level, PH1 is
caused by functional deficiencies in the liver-specific, pyridoxal-
dependent enzyme alanine-glyoxylate aminotransferase (AGT, EC
2.6.1.44) [3]. AGT catalyzes the transamination of the peroxi-
somal intermediary metabolite glyoxylate to glycin. Human AGT
consists of a 86 kDa homodimer and bears an atypical Lys-Lys-
Leu (KKL) peroxisomal targeting signal 1 (PTS1) motif at its C-
terminus, which is required for translocation of the enzyme into
peroxisomes. The absence of AGT in hepatic peroxisomes, owing
to either dysfunction or mistargeting of AGT, causes glyoxylate to
escape into the cytosol where it is further metabolized to oxalate
and glycolate. The accumulation of oxalate—a compound that
cannot be further metabolized in humans—leads to the progres-
sive formation of insoluble calcium oxalate in the kidney and
urinary tract, resulting in urolithiasis and/or nephrocalcinosis as
the principal clinical manifestations.
To date, around 150 polymorphic variants of the human AGXT
gene have been described [4]. These mutations are scattered over
virtually the entire encoded AGT sequence and the associated
three-dimensional structure of the enzyme (Figure S1). In 2%–
20% of human populations in geographically distinct regions, a
minor allele haplotype (AGXT-Mi) is found, which encodes an
AGT variant with two missense mutations (P11L, I340M). AGT-
Mi has around one-third of the catalytic activity of the wild-type
enzyme and reduced stability, yet by itself does not lead to a
serious clinical phenotype. However, the presence of AGXT-Mi in
combination with further mutations causes almost 50% of the
reported PH1, demonstrating synergistic disease effects [4]. Only
some of the characterized PH1-causing AGXT variants can be
directly correlated with AGT enzymatic activity, suggesting that
other molecular parameters such as its correct compartmental
localization have important implications for AGT function as well.
Therefore, it is not surprising that there is no uniform response by
PH1 patients to pyridoxine intake, which is thought to stabilize the
AGT active site but does not directly affect the localization of the
enzyme [5,6].
On the basis of biochemical and structural data, the molecular
mechanism of AGT catalytic activity is well established [7,8], but
the mechanism of peroxisomal AGT targeting is poorly under-
stood. The non-canonical PTS1 Lys-Lys-Leu sequence in human
AGT has been described as non-optimal, based on in vitro
interaction studies of chimeric proteins formed by fusing the motif
with non-human AGTs and other peroxisomal target proteins
PLoS Biology | www.plosbiology.org 1 April 2012 | Volume 10 | Issue 4 | e1001309[7,9]. Truncation studies of human AGT led to the prediction of
an additional binding site within the small C-terminal domain of
AGT, proximal to the established PTS1 C-terminus [9]. Another
non-overlapping AGT-Pex5p recognition segment was proposed
to be located close to the AGT N-terminus [10]. However, in the
absence of residue-specific interaction data, it is not known
whether additional interactions with the Pex5p receptor are direct
or mediated by putative adaptors, or even whether allosteric effects
are involved [3,11].
Moreover, a generalization of the interpretation of available
data is virtually impossible, as neither the PTS1 sequence nor a
consistent pattern for peroxisomal localization are taxonomically
conserved among AGTs from different species [12]. Indeed,
depending on the organism, AGTs have been found, partly in
parallel, in mitochondria, the cytosol, and peroxisomes [13].
Alternative transcription and translation sites in several AGTs lead
to elongated isoforms with an additional N-terminal mitochondrial
targeting signal sequence, which overrides the PTS1 required for
peroxisomal translocation [3,14]. Even in the absence of an
additional mitochondrial-targeting signal, residual mitochondrial
localization has been observed for AGT mutants that tend to
aggregate and misfold [4,14].
The aim of this work has been to unravel the role of non-PTS1
PH1 mutations in AGT mistargeting, to ultimately provide a
molecular model for genetically imprinted PH treatment. To
identify the complete Pex5p receptor-interaction site, we have first
determined the atomic structure of the AGT–Pex5p receptor
complex, which forms an elongated Pex5p-(AGT)2-Pex5p assem-
bly. In addition to the established PTS1-binding site, the structure
reveals extensive but rather non-specific contributions from
sequence segments of the C-terminal AGT domain. To test how
perturbations in the AGT structure could result in effects on
AGT–Pex5p receptor binding, we mutated several residues of the
AGT C-terminal domain near the Pex5p interface and investi-
gated the properties of the resulting mutants by biophysical and
functional in vitro and in vivo assays, as well as their ability to bind
Pex5p. The interactions observed are highly sensitive to any minor
changes in the AGT structure caused by single-residue muta-
tions—including those that have been identified in PH1 patients—
demonstrating that non-PTS1 interactions are essential in Pex5p
receptor recognition.
Results
Overall Structure of the Pex5p-(AGT)2-Pex5p Receptor–
Cargo Complex
To determine the molecular basis of the recognition of AGT by
the peroxisomal import receptor Pex5p and its implications in PH1,
we purified human AGT and the C-terminal cargo-binding segment
of human Pex5p (residues 315–639), referred to as Pex5p(C) [15].
The AGT–Pex5p(C) complex forms with an apparent (1:1)
stoichiometry and has a moderate dissociation constant of 3.5 mM
(Table 1). AGT, alone or in complex with Pex5p(C), has a catalytic
activity of close to 2,000 mMm g
21 h
21, which is in agreement with
previously reported AGT data [16,17] and suggests that binding to
Pex5p does not compromise AGT activity.
We then determined the crystal structure of the AGT–Pex5p(C)
complex at 2.4 A ˚ resolution (Figures 1 and S2; Table 2; Text S1).
The structure comprises an elongated Pex5p(C)-(AGT)2-Pex5p(C)
assembly with overall dimensions of around 140 A ˚650 A ˚650 A ˚.
The 1:2:1 stoichiometry of the complex is in agreement with our
isothermal titration microcalorimetry (ITC), gel filtration, and static
lightscatteringdata,indicating equalstoichiometriccontributions of
both protein components (Table S1 and Figure S3).
Each ofthetwocompleteAGTpolypeptidechainsisvisibleinthe
final electron density, except for N-terminal residues 1–3 and 1–5,
respectively. The overall conformation of the two AGT molecules is
identical (Table S2) and the structure shows that they both contain
the cofactor pyridoxal-59-phosphate (PLP) covalently bound to
Lys209 (Figure S4). We confirmed the AGT PLP-adduct to be
present by spectroscopic analysis of the protein material submitted
for crystallization (Figure S4C). The Pex5p(C)-bound AGT dimer
superimposes well onto that of the enzyme in the absence of the
receptor (PDB entry 1HOC) [8], with a root-mean-squares
deviation of 0.41 A ˚ (Table S2). This confirms that AGT dimeric
assembly and overall conformation,a prerequisiteforAGTcatalytic
activity [3], is not affected by Pex5p receptor binding.
Well interpretable electron density is visible for most of the two
Pex5p(C) receptor molecules (residues 315–639), with the exception
of the N-termini (residues 315–323/324), part of the distorted
tetratricopeptide repeat (TPR) 4 segment (residues 441–464, 444–
460) and the so-called 7C-loop (residues 591–592, 590–596) that
connects the 7-fold array of TPR segments with the C-terminal
bundle of Pex5p(C) [15]. These regions were either invisible or
mobile in previous structures of the same receptor [15,18],
indicating that these sequence segments are generally flexible.
Overall, increased flexibility of Pex5p(C), which we attribute to
these regions and to the loose arrangement of neighboring TPR
domain modules, is reflected in higher root-mean-squares devia-
tions of around 1 A ˚ when Pex5p(C) polypeptide chains of the
Pex5p(C)-AGT complex are either superimposed on each other or
onto the coordinates of the same receptor from the previously
determined Pex5(C)-SCP2 cargo complex (Table S2) [15].
By contrast, there are significant deviations in the overall
structure of Pex5p(C) bound to AGT when it is superimposed onto
the apo conformation of the same receptor (PDB entry 2C0M).
The matching part of the respective structures is limited to residues
of the 7-fold TPR array, excluding the C-terminal bundle domain.
Hence, the structure of the Pex5p(C)-AGT complex supports the
Author Summary
Peroxisomes are cell organelles contain proteins involved in
various aspects of metabolism. Peroxisome proteins trans-
locate from their site of synthesis in the cytoplasm across
the organelle membrane in a fully folded and functional
form. One such protein is the enzyme alanine–glyoxylate
aminotransferase (AGT). It contains a targeting signal in its
C-terminus that is recognized by a receptor protein, Pex5p,
in the cytoplasm, which allows its subsequent translocation
into the peroxisome. Mutations in AGT cause a disease
known as primary hyperoxaluria type 1, in which patients
suffer irreversible kidney damage; this disease results, in
many cases, from improper targeting of AGT into peroxi-
somes. To understand better the mechanism of AGT import
into peroxisomesandthe molecular basis of this disease,we
have determined the crystal structure of the complex
between AGT and its receptor Pex5p. The structure reveals
how overlapping segments of the protein sequence are
crucial for both receptor recognition and maintaining the
folded structure of the enzyme. Subsequently, we created
and studied several mutants of the enzyme, including
mutants that are known to cause disease, and found that
even minor folding defects in the enzyme prevent its
recognition by Pexp5 and its import into peroxisomes. Our
data thus provide novel insights into the consequences of
mutations in AGT on the catalytic activity of the enzyme, as
well as into the mechanisms that cause primary hyperox-
aluria type 1.
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previously on cargo binding [18,19].
Molecular Basis of AGT Recognition by the Pex5p
Receptor
The structure of the AGT–Pex5p complex reveals that the C-
terminal AGT domain (residues 283–392) is the exclusive and
direct binding module of the Pex5p receptor (Figures 1 and 2).
This domain comprises a bundle of the three helices a11 (residues
284–305), a12 (residues 332–343), and a13 (residues 370–387), in
which the two longest helices (a11, a13) are in a parallel
orientation to each other and the third (a12) crosses helix a13.
The three helices are connected by a small two-stranded b-sheet
(b8, residues 321–325; b9, residues 358–362) that forms an
interface with the N-terminal catalytic AGT transaminase
domain. The C-terminal sequence Pro-Lys-Lys-Lys-Leu (residues
Figure 1. Overall structure of the Pex5p(C)–AGT2–Pex5p(C) complex. Each of the two Pex5p(C) molecules is colored in cyan (TPR domains)
and violet (C-terminal helical bundle). The two AGT molecules are colored in green/grey (large catalytic domain), orange (C-terminal domain), and red
(PTS1 segment). The secondary structural elements of the C-terminal domain of one AGT protomer are labeled. Two PLP molecules, bound to each
AGT protomer, are shown in sphere presentation with atom-specific colors. The AGT-Pex5p binding interface can be subdivided into three surface
patches, labeled I–III. The specific interactions found in these interfaces are shown in Figure S5. A zoom of the complete interface is shown in
Figure 2A.
doi:10.1371/journal.pbio.1001309.g001
Table 1. Functional characterization of AGT variants.
Activity (mmol mg
21 h
21) AGT Localization (%)
a
AGT Variant 2Pex5p +Pex5p Pex5p Binding (mM) Peroxisomal
Wild-type 1,9756336 2,0206238 3.560.4 93.3
Y330W 2,0606263 2,0526179 7.961.0 66.7
Y330A 1,9326279 2,0736230 19.468.3 59.7
A328W 1,8226318 2,0256160 6.260.8 69.3
V376D
b ——— 1 . 7
L380D
b ——— 0 . 0
V376P
b ——— 0 . 3
L380P
b ——— 0 . 0
V336D 1,7006190 1,7756169 3.560.2 75.7
G170R 1,3196211 1,3966174 3.860.7 76.0
V336D/G170R
b ——— 2 8 . 0
aFor further details and standard deviations, see Figure 3.
bSoluble protein could not be obtained from heterologous protein expression.
doi:10.1371/journal.pbio.1001309.t001
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a13.
The overall AGT–Pex5p interface consists of three distinct
surface patches (Figures 1 and 2): the first involves the AGT-PTS1
(residues 389–392) that binds, as expected, into the central tunnel-
like cavity of the ring-forming array of seven TPR segments of
Pex5p(C), generating an interface of 550–600 A ˚ 2 (Interfaces Ia
and Ib in Figure 1; Figure S5, left panel). The second includes the
C-terminal part of the AGT helix a13 that immediately precedes
the PTS1 (residues 381–388) and the loop connecting b9-a12
(residues 327–330) that interacts with this part of a13 (Interfaces
IIa and IIb in Figure 1; Figure S5, central panel). We refer to this
site in AGT as the ‘‘extended PTS1’’ interface, as it is directly
upstream of the PTS1. Pex5p interactions from this interface
overlap with hydrophobic core contacts by residues from a13 with
other parts of the C-terminal AGT domain. Ala383, the most C-
terminal AGT residue that is entirely buried within the AGT fold,
is preceded by Arg381, which marks the most proximal residue in
a13 that contributes to the extended PTS1–Pex5p interface. The
third interface is topologically separate from the PTS1 and
involves the loop that connects AGT helix a11 and strand b8
(residues 303–307) (Interfaces IIIa and IIIb in Figure 1; Figure S5,
right panel). These two additional surface patches, when combined
with the PTS1 binding site, increase the overall AGT–Pex5p(C)
interface area by almost 2-fold, to around 1,000 A ˚ 2 (Table 3). A
detailed structural description of all the three interface patches is
provided in Text S1.
The three binding sites are topologically preserved in the two
AGT–Pex5p(C) modules. However, direct comparison reveals that
when using the structure of Pex5p(C) as the basis of superposition,
the orientation of the two bound AGT molecules deviate
substantially (Figures S5 and S6). If the two protein components
are assumed to be rigid bodies, the tilt and twist angles defining
their relative orientation [20] change by 27 and 11 degrees,
respectively. The difference originates from a limited conforma-
tional flexibility with a pivot point at the C-terminus of the AGT
helix a13, preceding the PTS1 motif. Owing to the rigidity of the
remaining AGT structure, the spatial differences in the superim-
posed complexes increase to around 20 A ˚ in those parts of each
AGT protomer that are most distal to the Pex5p(C) receptor-
binding site (Figure S6). Because of these conformational
differences, there is little conservation in the specific AGT–
Pex5p(C) interactions. With the exception of a few conserved
hydrogen bonds formed between three asparagines of Pex5p
(Asn415, Asn526, Asn561) and the C-terminal main-chain
carboxylate group of Leu392, along with the preceding peptide
bond connecting Lys391 and Leu392, the remaining side chains of
the AGT PTS1 sequence Lys389-Lys390-Lys391 are either not
involved in further specific interactions or, if observed, these
interactions are not conserved within the complete Pex5p-(AGT)2-
Pex5p complex (Figure 2 and Figure S5). These findings are in
agreement with an overall endothermic assembly process under
the experimental in vitro conditions, indicating that AGT–
Pex5p(C) complex formation is an entropy-driven process
(Tables 1 and S1) rather than being dominated by specific
enthalpic interactions.
Conformational Changes in the AGT C-Terminal Domain
Affect Pex5p Receptor Recognition
A key finding from our structural data is that binding of the
AGT PTS1 motif to the Pex5p receptor is not autonomous from
the additional cargo–receptor binding sites, both in terms of
sequence connectivity and surface topology. These data could
explain why many pathological AGT disease mutations that lead
to AGT mistargeting are remote from the Pex5p-binding site. On
the basis of our structural data, we argue that even minor folding
defects or conformational alterations in AGT could compromise
the binding of the AGT composite Pex5p interface, formed by the
AGT C-terminal domain and PTS1.
To address this assumption, we mutated several residues in the
AGT C-terminal domain close to the Pex5p-binding interface,
which we expected to lead to conformational changes in this
domain without compromising AGT activity (Figures 2 and S1).
The first set of mutations involved two residues from the b9–a12
loop (Ala328, Tyr330) that interact with residues from the C-
terminal helix a13 (Leu384 and Lys389). We introduced either
more bulky side chains (A328W, Y330W) or removed side chain-
specific intramolecular interactions (Y330A). For the second set of
AGT variants, we aimed to affect the hydrophobic interactions of
the C-terminal helix a13 with other parts of the AGT C-terminal
domain. For this purpose, we mutated two residues from this helix
(Val376, Leu380) that are completely buried into either an
aspartate or proline. Additionally, to provide a structural rationale
for established AGT disease mutations, we selected two AGT
single residue polymorphisms (G170R, V336D) and the corre-
sponding AGT double mutant G170R/V336D, which have been
found in combination with the minor allele haplotype (AGXT-Mi)
in PH1 patients. The AGT double mutant G170R/V336D results
in a serious pathogenic effect and is non-responsive to pyridoxine
treatment [2,4]. However, the disease-causing mechanism of this
AGT polymorphism, like various other mutations, has remained
Table 2. X-ray structure determination.
Pex5p(C)-AGT
Data collection
Space group P21
Cell dimensions
a, b, c (A ˚) 59.4, 99.2,127.7
a, b, c(u) 90.0, 96.7, 90.0
Resolution (A ˚) 78.1–2.35 (2.48–2.35)
Rmerge 11.5 (60.9)
I/sI 10.5 (2.0)
Completeness (%) 99.7 (97.9)
Redundancy 3.7 (3.4)
Refinement
Resolution (A ˚) 78.1–2.35
Number of reflections 57,997
Rwork/Rfree 18.7/23.9
Number of atoms
Protein 10,545
LYS-PLP 46
Water 831
B-factors
Protein 31.9
LYS-PLP 34.2
Water 31.5
R.m.s. deviations
Bond lengths (A ˚) 0.008
Bond angles (u) 1.082
doi:10.1371/journal.pbio.1001309.t002
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mutation from the C-terminal domain in conjunction with the
widespread G170R mutation seemed to be inexplicable, as the
latter (G170R) is coupled with unwanted mitochondrial import in
the AGXT-Mi isoform [21], again by an unknown mechanism of
action. A structure of the AGT G170R mutant revealed only
minor local conformational changes [22].
First, we attempted to purify all the AGT mutants to test their
ability to bind the Pex5p receptor in vitro and to measure their
catalytic activities (Table 1). However, the AGT variants with
mutations in residues of the C-terminal helix a13 (Val376,
Leu380) were insoluble when overexpressed in Escherichia coli,
demonstrating that the hydrophobic core interactions of helix a13
are essential for proper folding of the enzyme under the chosen
Figure 2. Structural basis of AGT recognition by the Pex5p receptor. (A) Zoom into the AGT-Pex5p(C) interface, depicting the side chains of
several key residues from this interface. AGT residues labels are in black, and Pex5p residues labels are in blue. Additional AGT residues near the
Pex5p interface, which are involved in hydrophobic core formation of the AGT C-terminal domain, are shown in green. Hydrogen bonds that are
structurally conserved in both independent AGT-Pex5p complexes are shown with dashed lines. (B) AGT binding surface of the Pex5p receptor, which
is almost 600 A ˚2 in size (cf., Table 3) and consists of a AGT PTS1 interface (red), surrounded by additional interface patches with other parts from AGT
(orange). The approximate locations of the seven TPR repeats in Pex5p are labeled I–VII. There are additional non-PTS1 binding sites around TPR
repeat II and the C-terminal bundle of the Pex5p receptor. The Pex5p complex that involves AGT chain A (cf., Figure 4) has been used for illustration.
Color codes in both panels are as in Figure 1.
doi:10.1371/journal.pbio.1001309.g002
Table 3. Protein cargo recognition by the Pex5p receptor.
AGT SCP2
Molecular weight 43 kDa 15 kDa
Association state dimer monomer
Interface (A ˚2) 1,067, 966 1,005
PTS1 interactions 211 (Arg381) to 0 (Leu392) 27 (Leu136) to 0 (Leu143)
C-terminal hydrophobic core interaction Cys387 Leu136
KD (protein cargo) (mM) 3.5 0.11
a
KD (PTS1) (mM) 13.5
b 0.66
KD gain cargo protein versus peptide 3.9 6.0
Cargo fold upon Pex5p binding Non-autonomous Autonomous
aData taken from [15].
bData taken from [26].
doi:10.1371/journal.pbio.1001309.t003
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for the pathogenic AGT double mutant G170R/V336D, whereas
each of the two single residue variants (G170R, V336D) could be
expressed in significant quantities as soluble proteins. Although the
aggregated AGT mutants could not be further characterized in
vitro, they were used in functional assays to assess their tendency
for aggregation in vivo and to investigate the level of peroxisomal
targeting from AGT versions with suspected folding defects (see
below).
All remaining mutants were purified by affinity chromatography
and gel filtration (Figure S3). Proper folding of each protein was
confirmed by far-UV circular dichroism spectroscopy (Figure S3).
These AGT mutants had catalytic activities similar to the wild-
type enzyme irrespective of Pex5p binding with the exception of
the G170R mutant, which showed a decrease in activity of around
25%, in qualitative agreement with previous data [17]. Whereas
the two pathogenic AGT single-residue mutants (G170R, V336D)
did not show a significant change in Pex5p receptor binding, the
AGT variants with mutations in the b9–a12 loop showed 2- to 6-
fold decreased binding affinities for the Pex5p receptor when
compared with the wild-type enzyme (Table 1). The weakest
interaction, with a Kd of 19.468.3, was found for the Y330A AGT
variant, indicating an important contribution of the side chain of
Tyr330 to keep the b9-a12 loop in a conformation that is
competent for Pex5p receptor binding. As for wild-type AGT,
Pex5p binding by all of the AGT mutants is endothermic under
the in vitro experimental conditions (Table S1).
To test the functional properties of all selected AGT variants in
vivo, we employed a protein import assay in human fibroblasts,
using enhanced green fluorescent protein (EGFP)-tagged AGT.
When expressing EGFP-AGT without further modification in
fibroblasts, we observed that more than 90% of the cells exhibited
a punctuated pattern of peroxisomal localization (Figure 3). By
contrast, a control version of the enzyme without the PTS1
(DPTS1) was evenly distributed in the cytosol without any visible
sign of peroxisomal import (Figure S7), confirming that the
presence of a PTS1 in AGT is crucial for recognition by the Pex5p
receptor.
None of the AGT helix a13 variants showed significant
measurable peroxisomal translocation, suggesting that fold defects
in AGT lead to an almost complete loss of Pex5p import (Table 1;
Figure 3). Aggregation of these AGT versions under in vivo
experimental conditions is reflected by the formation of large
fluorescent plaques in the cytosol, which are abundant in 28%–
100% of transfected cells. This indicates substantial variability
depending on the AGT mutant investigated. Whereas
AGT(L380P), for instance, aggregates completely (Figure 3B),
other AGT mutants (V376D, L380D) reveal a predominantly
cytosolic background, suggesting a soluble cellular state with no
peroxisomal association (Figure S7). These observations indicate
that both misfolding and local conformational changes in the C-
terminal domain have a synergistic effect, leading to a loss of AGT
targeting to peroxisomes. The data also suggest that indirect
effects, arising from altered structural properties of the AGT
cargo, rather than direct and specific receptor interactions, are
sufficient to abolish proper cargo recognition by the Pex5p
receptor for peroxisomal targeting.
A slightly milder effect was observed with the pathogenic double
mutant G170R/V336D, with 28% of the protein-forming plaques
in the cytosol, and another 28% being properly translocated into
peroxisomes (Figure 3). The overall level of non-peroxisomal
localization of this AGT mutant is 72%. All remaining AGT
variants, including those from the b9–a12 loop and the two
pathogenic single-residue mutants (G170R, V336D), displayed
59%–76% peroxisomal localization, which is in agreement with
our in vitro binding data and indicates a weakening but not an
abolishment of Pex5p binding. Two AGT mutants from this
category (G170R, A328W) showed around 5% aggregation,
whereas no significant level of aggregation was measured for the
remaining mutants. Taken together, the data show that even
minor structural perturbations in AGT have a measurable and
significant effect on AGT translocation.
Discussion
AGT Is Recognized by the Pex5p Receptor as Oligomeric
and Functional Cargo
The AGT–Pex5p structure is the second cargo protein–Pex5p
receptor complex determined to date, the first being sterol carrier
protein 2 (SCP2)–Pex5p [15]. Our data indicate that the dimeric
and cofactor-bound arrangement of AGT is preserved and that
the enzyme remains functional prior to and upon binding of the
Pex5p receptor (Table 1). This observation is in agreement with
the unique ability of peroxisomes to import even large and
oligomeric cargos as functional protein assemblies [23–25]. As our
studies have been carried out in the absence of any additional
protein components, a potential requirement of adaptor proteins
as previously suggested [9,11] is unlikely. Our data confirm the
involvement of segments from the C-terminal AGT domain—
previously described as the ‘‘PTS1A’’ binding site [9]—in Pex5p
receptor binding, but do not support earlier suggestions that an N-
terminal AGT sequence segment contributes to receptor recogni-
tion [10].
Non-Autonomous PTS1 Recognition by the Pex5p
Receptor
Comparison of the complexes of Pex5p with SCP2 and AGT
allows for the first time the identification of common and diverging
principles in target protein recognition (Table 3), beyond the well-
established C-terminal PTS1 motif that is shared by most Pex5p
cargos [26]. Notably, the measured AGT–Pex5p interaction is
about 30-fold weaker than that observed for SCP2. This argues in
favor of AGT being highly sensitive to perturbations that affect
Pex5p recognition (Table 1; Figure 3) and may mirror the large
number of known disease-causing AGT mutations that have been
associated with protein mistargeting rather than with catalytic
activity effects [4].
The two protein cargo–receptor complex structures reveal that
there are almost no specific, conserved side-chain interactions
between polar residues from each PTS1 motif with Pex5p, with
the notable exception of the very C-terminal leucine residue
(Figure 4). This observation is supported by previous findings on
AGT that indicate side-chain tolerance at PTS1 position 23 and,
albeit more limited, at position 21 [27]. By contrast, our data only
partly agree with observations from Pex5p–PTS1 peptide
complexes, in which a more extensive hydrogen bond network
over several PTS1 residues was observed [25,28,29]. Comparison
with the available Pex5p–cargo protein complex structures
indicates that the adaptability of possible PTS1 conformations to
optimize specific interactions with the Pex5p receptor is restricted
owing to the additional non-PTS1 protein interfaces that are
formed between the C-terminal bundle domain of the receptor
and cargo, as previously shown for SCP2 [15,30] and for AGT in
this contribution (Figure 2). Collectively, however, the additional
non-PTS1 interactions (marked as IIa,b and IIIa,b in Figure 1)
only slightly enlarge the overall Pex5p–AGT interface, in
comparison to that observed in the Pex5p-SCP2 complex, in
one of the two Pex5p-AGT complexes (Table 3).
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corresponding to AGT and SCP2 sequences, are weak, with
dissociation constants in the low to sub-mM range [15,26]. The
gain in binding affinity for AGT when the complete protein is used
is around 4-fold—3.5 mM instead of 13.5 mM (Table 3). Similarly,
a gain in binding affinity of around 6-fold has been found for
SCP2–Pex5p assembly when the protein complex is compared
with the corresponding PTS1 peptide complex [15]. However, a
recent analysis of additional non-PTS1 interactions confirmed that
their contribution is only of minor importance, in turn suggesting
that SCP2 recognition by the Pex5p receptor is principally driven
by autonomous recognition of its PTS1 motif [30]. By contrast,
our structural and functional data on AGT–Pex5p show that
complex formation is both dependent on the presence of the AGT
PTS1 motif and the correct Pex5p binding-competent conforma-
tion of the AGT C-terminal domain. Based on these findings, we
argue that previously reported problems in establishing in vitro
binding with purified protein components and by transfection
experiments have failed for several PTS1 protein cargos in vivo
owing to contextual defects in protein folding and possibly
oligomerization [31,32]. Moderate binding of the cargo in vivo
may facilitate subsequent release of the cargo into the peroxisomal
lumen, a process that at present is still less well understood than
the mechanism of cargo binding [18,33,34].
Further investigation of our structural data of the AGT–Pex5p
complex reveals that the sequence segments in AGT that
constitute the PTS1 and the hydrophobic core of AGT
topologically overlap, whereas in SCP2 the corresponding
sequence segments are well separated (Figure 5). Specifically, the
PTS1 interactions observed extend to Arg381 (PTS1 position
211, when considering the C-terminal Leu392 as position 0), and
the side chains of three residues within the extended PTS1
segment (Ala383, Leu384, Cys387) are also involved in hydro-
phobic core interactions of the C-terminal AGT domain. The
overlapping interactions thus generate a seven-residue segment
(381–387) from the C-terminus of helix a13 (Figure 2A) [8] that is
involved in both the overall AGT fold and Pex5p receptor
recognition. These structural observations indicate that, in
contrast to our previous findings on the SCP2–Pex5p complex
[15], Pex5p receptor recognition of the PTS1 in AGT is
Figure 3. Subcellular distribution of AGT variants. (A) Human fibroblast cells were transfected with plasmids expressing EGFP-fused AGT
variants, which are labeled. Congruent punctuate fluorescence pattern of wt-EGFP-AGT and Pex14p demonstrates peroxisomal localization.
Additional diffuse cytosolic staining obtained for all mutants indicates partial cytosolic mislocalization. Large fluorescent patches that are not
congruent with the characteristic peroxisomal pattern are the result of protein aggregation. Size bars, 10 mm. Additional images are shown in Figure
S7. (B) Histogram showing the percentages of transfected cells displaying distinct EGFP-AGT localization patterns (green, peroxisomal; blue, cytosolic;
red, aggregates). Standard deviations are shown with error bars.
doi:10.1371/journal.pbio.1001309.g003
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the enzyme. Our structural data also explain previous observations
on the translocation of AGT molecules that contain mutations in
the extended PTS1 motif. These studies showed that diminished
binding is caused by folding defects rather than by loss of cargo–
receptor interactions that were predicted prior to available
structural data [27], indicating that AGT PTS1 binding depends
on properly folded AGT and thus is also functionally non-
autonomous. This is well illustrated by the strong translocation
defects of several extended PTS1 mutations in AGT (L380P;
V376P) [27], which are involved in AGT hydrophobic core
interactions rather than specific AGT–Pex5p interactions
(Figure 5).
In AGT, the additional Pex5p non-PTS1 interactions observed
are not as specific as one may expect (Figures 2A and S5) and
perhaps explain the moderate overall binding affinity. These
findings are further supported by the observation that Pex5p–
AGT binding in vitro is an entropy-driven process, suggesting that
binding is dominated by order/disorder processes rather than by
enthalpy-driven specific interactions.
Towards New Approaches to Restore AGT Function in
Disease Treatment
AGT is an enzyme with a well-established genotype/phenotype
database, including about 150 different missense mutations, many
of which lead to serious forms of PH. Our structural and
functional characterization of the molecular parameters for AGT
to be recognized by the Pex5p receptor and its subsequent
translocation into peroxisomes offers an opportunity to rationally
address functional implications of pathogenic PH-causing missense
mutations.
We assume that those PH mutations that lead to irreversible
AGT aggregation, irrespective of the presence of the Pex5p
receptor, will be difficult or even impossible to treat by chemical
intervention as these AGT variants are expected to lose both their
enzymatic activity and their ability to be recognized by the
peroxisomal Pex5p receptor as a consequence of misfolding. Based
on our mapping of known AGT missense mutations on the three-
dimensional structure of the AGT–Pex5p complex (Figure S1), we
estimate that around half of these lead to fold defects, as they
reside in regions that are completely buried within the AGT fold.
The fraction of misfolded AGT mutants is probably even higher
when associated with the widespread AGXT-Mi gene [3], which
leads to additional destabilization of the enzyme. Partial rescue of
some of these mutations, by adding chaperones or osmolytes for
instance [35], may be possible but remains challenging, as most of
these additives tend to be non-specific.
On the basis of our data, we further expect that the loss of
function of many of the remaining patient mutations (Figure S1)
that result in AGT, which does not aggregate or is only partially
prone to aggregation, could be potentially restored by proper
chemical intervention. As the topology of the AGT active site is
well characterized by PLP binding (Figure S4) and the presence of
several highly conserved residues, mutations that directly affect
AGT enzymatic activity are predictable and their effect can be
verified by AGT activity tests [4,5]. For mutants of this category, it
has been shown that pyridoxine treatment may lead to additional
active-site stabilization, resulting in a reduction of clinical
symptoms such as calcium oxalate crystallization and an increasing
preservation of renal function [36].
However, prior to this work, a rational basis for predicting
mutations involved in the loss of peroxisomal targeting has been
largely missing. A paradigm pathogenic mutation within this
category is the G170R/V336D variant located on the AGXT-Mi
allele [36], which creates a serious disease phenotype. For this type
of mutation, which predominantly affects peroxisomal targeting, it
Figure 4. Comparison of PTS1–receptor interactions, based on the receptor complexes with AGT (chains A and B) and SCP2. The
respective PTS1 sequences are shown to the left and to the right. Hydrogen bonds with the receptor are indicated with dashed lines (black
characters, main-chain interactions; red characters, side-chain interactions; background colors are as in Figure 1). Those interactions in the AGT–Pex5p
complex that are structurally conserved are boxed.
doi:10.1371/journal.pbio.1001309.g004
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AGT binding to the Pex5p receptor, by targeting identified AGT–
Pex5p interface areas such as the PTS1 site, the extended PTS1
site, and relevant Pex5p-binding surfaces from the AGT C-
terminal domain (Figures 1–2 and S5). The knowledge of designed
AGT variants compromised in Pex5p recognition, such as
AGT(Y330A), may be useful for targeting the restoration of
AGT–Pex5p recognition to wild-type levels. The observed limited
flexibility in the non-PTS1 binding areas and the lack of optimized
interactions within the PTS1 binding site of AGT (Figures S5 and
S6) may provide a knowledge-based system by which Pex5p
receptor binding can be maximized by compounds that have the
potential to improve protein-protein interactions.
Materials and Methods
Cloning and Protein Expression
Human AGT (major allele haplotype) and human Pex5p(C)
(residues 315–639) were expressed from a modified pET24d vector
(G. Stier, EMBL Heidelberg) in Escherichia coli BL21(DE3) RIL.
The two genes were amplified by polymerase chain reaction (PCR)
using primers containing NcoI and KpnI restriction sites,
respectively (Table S4). Following the digestion of the PCR
products and the vector, the two constructs were created by
ligation (Rapid Ligation Kit, Fermentas). Cultures were grown in
Lysogeny Broth medium containing 50 mM Tris pH 7.5 and 1%
(w/v) glucose, and induced mid-log phase with 0.5 mM isopropyl-
b-D-thiogalactopyranosid overnight at 21uC. Both proteins
contained an N-terminal hexahistidine–glutathione S-transferase
fusion, which is cleavable with tobacco etch virus (TEV) protease.
The cleared lysate was loaded onto a nickel-nitrilotriacetic acid
column and the purified proteins were eluted with 50 mM Tris
pH 8.0, 150 mM NaCl, 2 mM ß-mercaptoethanol, and 500 mM
imidazole. Fusion proteins were cleaved with tobacco etch virus
protease overnight at 4uC, along with dialysis into 50 mM Tris
pH 8.0, 150 mM NaCl, 2 mM ß-mercaptoethanol, and 20 mM
imidazole. The samples were then applied to a nickel-nitrilotria-
cetic acid column and the flow-through was collected. As a final
purification step, gel filtration was performed using a Superdex 75
(16/60) column (GE Healthcare).
In vivo analysis of EGFP-AGT was carried out with the
expression vector pEGFP-AGT, which was derived from subclon-
ing a PCR amplification product of AGT into the pEGFP-C1
plasmid (Clontech). Point mutations were introduced into pEGFP-
AGT by using the Quickchange XL Site Directed Mutagenesis Kit
(Stratagene). All primers are listed in Table S3.
AGT point mutants that were tested in vitro were subcloned
into a pET151 D-TOPO vector. Expression and purification of
these proteins was performed as described above.
Complex Formation, Characterization, and Enzyme Assay
The Pex5p(C)–AGT complex was formed by mixing purified
Pex5p(C) and AGT and confirmed by analytical gel filtration and
static light scattering, using a MiniDAWN instrument (Wyatt).
Specific activity measurements of AGT in the presence and
absence of Pex5p were performed as described previously [37,38],
using the following concentrations: 100 mM potassium phosphate
pH 8.0, 0.15 mM PLP, 10 mM glyoxylate, and 150 mM alanine.
To confirm specific binding of the cofactor to the recombinant
enzyme, we recorded absorption spectra between 300 and
600 nm. All measurements were performed on an Infinity 1000
spectrophotometer (Tecan).
Crystallization and X-Ray Structure Determination
Pex5p(C) and AGT were mixed in a 3:2 molar ratio and
concentrated to 5 mg/ml. Crystals were obtained by submitting a
mix of 1 ml protein and 1 ml reservoir solution, comprising 0.1 M
Figure 5. Comparison of Pex5p receptor and hydrophobic core interactions in SCP2 (left) and AGT (right). Green bars, accessible
surface area per residue; blue bars, interaction surface with Pex5p receptor. Residues with side chains involved in cargo hydrophobic core are labeled
with green dots. In contrast to SCP2, there is a seven-residue segment in AGT (381–387) that contributes to the core of the AGT fold and to Pex5p
receptor interactions (red dashed line).
doi:10.1371/journal.pbio.1001309.g005
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hanging drop vapor diffusion at 20uC. Streak seeding of a drop
with 2.5 mg/ml protein concentration was used to obtain single
large crystals.
X-ray data were collected at BM14.1 at ESRF, Grenoble. Data
were processed with MOSFLM [39] and scaled with SCALA [40].
Five percent of the reflections were randomly selected for cross-
validation. The structure of the Pex5p(C)–AGT complex was
solved by molecular replacement using the coordinates of apo-
AGT (PDB code: 1H0C) and the Pex5p–SCP2 complex (PDB
code: 2C0L) as search models with the program PHASER [41].
REFMAC [42] was used to refine the structure, applying
translation/libration/screw parameterization [43]. Manual build-
ing and structure analysis were carried out in COOT [44]. The
structure quality was assessed with MOLPROBITY [45].
Programs of the CCP4 package [46] were used for structure
manipulation, analysis, and validation. The coordinates of the
structure have been deposited in the Protein Data Bank (code:
3R9A). Tilt and twist angles were calculated using MOD22 [20].
Isothermal Titration Microcalorimetry
All proteins were dialyzed against 100 mM HEPES (pH 7.5),
150 mM NaCl, and 2 mM ß-mercaptoethanol. ITC measure-
ments were conducted on a MicroCal VP-ITC using 25–46 mM
AGT as a sample and 250–460 mM Pex5p(C) as a titration ligand.
Experiments were performed at 25uC. Pex5p(C) was injected in
volumes of 10 ml in a total of 27 steps, resulting in a 2-fold excess of
AGT at the end of each titration experiment. Ligand heating
effects by dilution were subtracted, and data were fitted using
MicroCal Origin 5.0.
Circular Dichroism
Circular dichroism experiments were performed on a J-810
spectropolarimeter (Jasco). Proteins were dialyzed into 10 mM
potassium phosphate (pH 8.0) and 1 mM dithiothreitol. Far-UV
spectra were recorded between 190 and 260 nm, using a 1 mm
cuvette and a concentration of 0.15–0.22 mg/ml protein, as
determined by specific absorbance at 280 nm. The machine
settings were 1 nm bandwidth, 1 s response, 1 nm data pitch, and
100 nm/min scan speed. Secondary structure content was
calculated with the Diochroweb server [47], using the analysis
program CDSSTR and reference set 4. All circular dichroism data
presented are the averages of three separate experiments.
Localization Assay
Human fibroblast cells (strain GM5756T) were cultured as
described previously [15] and transfected with pEGFP-AGT
variants, using FuGENE 6 Transfection Reagent (Roche Diag-
nostics). At 24 h after transfection, cells were fixed with 3%
paraformaldehyde, solubilized with 1% Triton X-100, and
subjected to immunofluorescence microscopy. Polyclonal rabbit
antibodies against Pex14p were used to label peroxisomes [48].
Secondary antibodies were conjugated with Alexa Fluor 594
(Invitrogen, Germany). All micrographs were recorded on an
Axioplan 2 microscope (Zeiss) with a Plan-Apochromat 636/1.4
oil objective and an Axiocam MR digital camera and were
processed with AxioVision 4.6 software (Zeiss). Statistical analysis
was carried out from at least three independent transfections of
each AGT expression plasmid. Based on the appearance of the
AGT fluorescence pattern, around 100 cells of each experiment
were visually categorized into three classes: (i) predominant
peroxisomal localization, (ii) mostly cytosolic, or (iii) forming
aggregates, as indicated by fluorescent plaques over cytosolic
background.
Supporting Information
Figure S1 Missense mutations and designed mutations in AGT.
In the green/orange AGTprotomer,knownmissense mutations are
shown by red spheres, indicating that they are distributed over the
entire AGT structure. In the grey/orange AGT protomer, designed
single residues and selected missense mutationsare shown with cyan
and blue spheres, respectively, and are labeled. The two PLP
cofactors are indicated in stick presentation, using atom-specific
colors. The color code of the shown ribbon is as in Figure 1.
(TIF)
Figure S2 Stereo image of the PTS1 of AGT (residues 385–392),
within a final 2Fo-Fc electron density at 1s contour level. The
structural framework of the Pex5p(C)-AGTcomplex is indicated by a
cartoon presentation in faint colors, using the color codes of Figure 1.
(TIF)
Figure S3 Biophysical characterization of AGT variants. (A)
Purity of AGT mutants were analyzed by SDS-PAGE. Lane
annotations: Marker; 1, AGT(wt); 2, AGT(A328W); 3, AG-
T(Y330A); 4, AGT(Y330W); 5, AGT(V336D); 6, AGT(G170R).
(B) Analysis of the oligomeric state of the Pex5p(C)-AGT complex
and single protein components by analytic gel filtration and static
light scattering. Color codes: Pex5p(C), green; AGT, blue;
Pex5p(C)-AGT, red. The molecular weights of the peaks in the
elution profiles are measured at 34.2 kDa, 83.4 kDa, and
142 kDa, respectively, which correlate well with the calculated
molecular weights of Pex5p(C) (36 kDa), AGT (86 kDa), and a 2:2
Pex5p (C):AGT complex (158 kDa). (C) Circular dichroism
spectra for purified AGT mutants (cf., panel A). The estimated
secondary structural content for each mutant is summarized in
Table S3.
(TIF)
Figure S4 Evidence for the presence of a Lys209-PLP adduct in
the Pex5-AGT complex. (A and B) Lys209-PLP (yellow)
interaction network in AGT chains A (green) and C (grey),
respectively, within the AGT-Pex5p complex. Residues from the
other AGT protomer within each of the two PLP-binding sites are
shown in chain-specific colors. The final electron density map for
each Lys209-PLP is shown at 1.0s contour level. Interacting
residues are shown in stick representation and are labeled. (C)
Absorption spectra were recorded for AGT protein solutions at
pH 7.5 (green) and pH 5.3 (red), which represents the pH used for
crystallization. Maximum absorbance was measured at 420 nm,
indicating the presence of an internal aldimine, as observed in the
crystal structure (cf., panels A and B).
(TIF)
Figure S5 AGT-Pex5p interface patches, divided in three areas
entitled ‘‘PTS1,’’ ‘‘extended PTS1,’’ and ‘‘C-terminal domain.’’
Both AGT-Pex5 interfaces from the overall Pex5p-(AGT)2-Pex5p
complex are shown separately (upper and lower panel) and are
labeled (Ia, Ib, IIa, IIb, IIIa, IIIb) according to Figure 1.
Interacting residues are shown in stick presentation and are
labeled. Hydrogen bonds are shown with dashed lines. Note that
various interactions are not conserved in the two AGT-Pex5p
complexes. Color codes are as in Figure 1.
(TIF)
Figure S6 Differences in the overall arrangement of the two
AGT-Pex5 complexes. The two complexes are superimposed
using the coordinates of the Pex5p receptor and are shown in two
different orientations, differing by 90u around a vertical axis.
Spatial differences between the two AGT molecules bound to
Pex5p are indicated to the left and are translated into distance
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PLoS Biology | www.plosbiology.org 10 April 2012 | Volume 10 | Issue 4 | e1001309range-specific color codes in one of the two superimposed AGT
molecules, whereas the other one is colored in grey. The difference
of the Pex5p–AGT arrangement in the two complexes has also
been measured by a tilt/twist angle analysis.
(TIF)
Figure S7 Localization of additional AGT variants. Human
fibroblast cells were transfected with plasmids expressing EGFP-
fused AGT variants. Truncation of the C-terminal PTS1 of AGT
results in non-punctuated diffuse staining, indicating cytosolic
mislocalization (DPTS1). The other AGT mutants (V376D,
L380D, L380P) form large fluorescent patches that are not
congruent with the characteristic peroxisomal pattern (aHsPex14)
suggesting protein aggregation. Size bars, 10 mm.
(TIF)
Table S1 Quantitative determination of Pex5p interaction with
AGT mutants by isothermal titration microcalorimetry. The
average stoichiometry calculated from all performed measure-
ments is 1.0260.05.
(DOC)
Table S2 Comparison of the structure of AGT and Pex5p.
(DOC)
Table S3 Estimated secondary structure content of purified
AGT variants.
(DOC)
Table S4 Primer sequences used.
(DOC)
Text S1 Detailed description of AGT-Pex5p interface interac-
tions.
(DOC)
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